Literature DB >> 25013716

Hemophagocytic lymphohistiocytosis and pelger-huët anomaly associated with colchicine intoxication.

Baris Malbora1, Emine Polat2, Sare Gulfem Akyuz3.   

Abstract

Colchicine is frequently used in the treatment of familial Mediterranean fever (FMF). First symptoms of colchicine intoxication are gastrointestinal disturbances, such as abdominal cramps, diarrhea, pancytopenia and so on. Herein, we report a female FMF patient with pancytopenia and hemophagocytic lymphohitiocytosis (HLH), following colchicine intoxication for committing suicide. To our knowledge, this is the first reported case of a patient with HLH associated with colchicine intoxication.

Entities:  

Keywords:  Pelger-Huët anomaly; colchicine intoxication; hemophagocytic lymphohitiocytosis

Year:  2014        PMID: 25013716      PMCID: PMC4091288          DOI: 10.4081/hr.2014.5356

Source DB:  PubMed          Journal:  Hematol Rep        ISSN: 2038-8322


Introduction

Colchicine is a widely used drug for treatment of familial Mediterranean fever (FMF). Clinical manifestations of colchicine intoxication include abdominal cramps, diarrhea, myotoxicity, hemolytic anemia and (pan)cytopenia.[1-3] Yet, colchicine intoxication related hemophagocytic lymphohitiocytosis (HLH) has not been reported.

Case Report

A 9-years-old female patient, receiving colchicine for four months with a dose of 1 mg/day for FMF, was admitted to a hospital with gastrointestinal disturbance four days ago. She was referred to our hospital with liver and kidney dysfunction. At the initial physical examination the patient’s general condition was moderate, and she was conscious. Her weight was 30 kg. She had hepatomegaly. Her laboratory results revealed: hemoglobin 13.6 g/dL; leukocyte, 9.6×109/L; thrombocyte 57×109/L; fibrinogen 157 mg/dL (230-500); PT 26.1 sec; INR 2.3; aPTT 43.8 sec; LDH 5329 IU/L; AST 630 IU/L; ALT 52 IU/L; ferritin 2320 µg/L (10-55); triglyceride 7.1 mmol/L (0.32-1.46). Microbiologic serologies were negative. The patient was taken to intensive care unit; vitamin K and fresh frozen plasma were administered. On the second day of her hospitalization, she had 39°C fever and splenomegaly. Hemoglobin was 9.6 g/dL; leukocyte was 2.3×109/L; neutrophil was 0.72×109/L and thrombocyte was 24×109/L. On peripheral blood smear, loss of lobulation in neutrophils was detected (Pelger-Huët anomaly). Laboratory tests revealed ferritin 54,632 µg/L, triglyceride 7.4 mmol/L, and fibrinogen 63 mg/dL, serum creatinine 3.2 mg/dL (0.4-1.4), serum blood urea nitrogen 43 mg/dL (6-21), serum sodium 131 meq/L (134-148), potassium 5.2 meq/L (3-4.8), calcium 8.1 mg/dL (7.9-9.9), and inorganic phosphate 2.1 mg/dL (2.4-4.7). At the bone marrow aspiration, many Pelger-Huët cells were observed. Hemophagocytosis was detected (Figure 1). Soluble CD25 level was 2840 U/mL (220-710), and creatine kinase level was 18,959 IU/L. Myoglobinuria was spotted.
Figure 1.

Pelger-Huët anomaly with a unilobed ovoid nucleus. The nucleus is smaller with more compact and densely staining chromatin on the peripheral blood smear (A) and bone marrow aspiration (C) (Wright-Giemsa, 100×, oil immersion). Pelger-Huët anomaly with bilobed polymorphonuclear leukocyte with a short, thick nucleus and dense, darkly staining chromatin, most consistent with a mature PMN on the peripheral blood smear (B) (Wright-Giemsa, 100×, oil immersion). Bone marrow aspirate of the patient showing phagocytosis of platelets (D) (Wright-Giemsa, 100×, oil).

When the history of colchicine intoxication was detailed, during FMF attack-free period of five days prior to admission to the hospital, it is learned that the patient was upset over a quarrel between her parents, and that she had taken approximately 30 pills of her drug (total of 15 mg; 0.5 mg/kg body weight), at which vomiting and diarrhea complaints were started. Then laboratory and clinical findings of the HLH have emerged. The patient was administered HLH-2004 protocol and plasma exchange is applied twice. On the second day of therapy, severe hypotension, renal failure and AV complete block occurred. The patient was resistant to all therapies and had died at the fourth day of her hospitalization.

Discussion and Conclusions

In the colchicine intoxication, the most affected organs are those that have a rapid cell turnover. First symptoms of acute toxicity are gastrointestinal disturbances. Liver damage, renal failure, arrhythmias, neuromuscular disturbances, and bone marrow depression can be detected in the later stage.[3,4] The worst predicted doses were classified regarding the risk of toxicity as sub-toxic (<0.5 mg/kg), toxic (0.5-0.8 mg/kg), and lethal (>0.8 mg/kg) doses.[5] However, cases with cardiogenic shock and death were also reported with doses less than 0.5 mg/kg.[6] Although our patient had taken a dose of 0.5 mg/kg body weight colchicine, the patient died due to severe myelosupression, HLH and multi-organ failure. Pelger-Huët anomaly is a state of limitation in segmentation of lobes in neutrophils. A Pelger-Huët-like change in granulocyte morphology may occur as an acquired condition in several diseases.[7,8] This same finding may be produced by certain drugs such as colchicine.[9] On the peripheral blood smear of our patient, Pelger-Huët cells were detected in myeloid series, and as the history of colchicine use was detailed, it is learned that the patient had taken lots of colchicine pills. On the examination of concurrently taken bone marrow, Pelger-Huët cells were also detected in the myeloid series as well as hemophagocytosis. Association between HLH and FMF has been shown.[10,11] Although our patient had FMF diagnosis, she was in stabile state. For this reason, we suggest that HLH was not due to her disease. To our knowledge, this is the first reported case of a patient with HLH associated with colchicine intoxication. In conclusion, if patients with colchicine intoxication present with Pelger-Huët anomaly in addition with unexplained fever, cytopenia, organomegaly, and biochemical changes, HLH should be investigated for prompt diagnosis and treatment.
  11 in total

1.  Macrophage activation syndrome revealing familial Mediterranean fever.

Authors:  L Rossi-Semerano; B Hermeziu; M Fabre; I Koné-Paut
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-05       Impact factor: 4.794

Review 2.  Colchicine today.

Authors:  Elisabeth Niel; Jean-Michel Scherrmann
Journal:  Joint Bone Spine       Date:  2006-09-01       Impact factor: 4.929

3.  The preleukemic syndrome.

Authors:  J W Linman; M I Saarni
Journal:  Semin Hematol       Date:  1974-01       Impact factor: 3.851

4.  Hemophagocytic syndrome in a child with severe Crohn's disease and familial Mediterranean fever.

Authors:  Nuray Uslu; Hulya Demir; Gunay Balta; Inci N Saltik-Temizel; Hasan Ozen; Figen Gürakan; Aysel Yüce
Journal:  J Crohns Colitis       Date:  2010-01-06       Impact factor: 9.071

5.  Late diagnosis of severe colchicine intoxication.

Authors:  Ayfer Gür Güven; Elif Bahat; Sema Akman; Reha Artan; Meltem Erol
Journal:  Pediatrics       Date:  2002-05       Impact factor: 7.124

6.  Assessment of the association between colchicine therapy and serious adverse events.

Authors:  Brittany A Todd; Sarah J Billups; Thomas Delate; Kara E Canty; Amy B Kauffman; Julia E Rawlings; Theresa M Wagner
Journal:  Pharmacotherapy       Date:  2012-09-27       Impact factor: 4.705

Review 7.  Understanding and recognizing the Pelger-Huët anomaly.

Authors:  Rita Colella; Sandra C Hollensead
Journal:  Am J Clin Pathol       Date:  2012-03       Impact factor: 2.493

8.  Multiple organ failure after an overdose of less than 0.4 mg/kg of colchicine: role of coingestants and drugs during intensive care management.

Authors:  Virginie Montiel; Vincent Huberlant; Marie-Françoise Vincent; Frédéric Bonbled; Philippe Hantson
Journal:  Clin Toxicol (Phila)       Date:  2010-08-12       Impact factor: 4.467

9.  Accidental colchicine overdose. A case report and literature review.

Authors:  M J Maxwell; P Muthu; P E Pritty
Journal:  Emerg Med J       Date:  2002-05       Impact factor: 2.740

10.  Two cases of acute leukopenia induced by colchicine with concurrent immunosuppressants use in Behçet's disease.

Authors:  Kyu-Yeop Lee; Do Young Kim; Jae Yong Chang; Dongsik Bang
Journal:  Yonsei Med J       Date:  2008-02-29       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.